[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cervical-cancer-screening-methods\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cervical-cancer-screening-methods":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,50,82],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100635232","digital-telecytology-for-triage-of-hpv-positive-women-in-cameroon-100635232",false,"NCT07550010","Digital Telecytology for Triage of HPV-Positive Women in Cameroon","Evaluation of Digital Cytology for the Triage of HPV-positive Women in a Same-day \"Test-triage-treat\" Cervical Cancer Screening Strategy in Cameroon","Inclusion Criteria:\n\n* HIV-negative women aged 30-49 and HIV-positive women aged 25-49 years old\n* Ability to understand study procedures and accepting voluntarily to participate by signing an informed consent form (ICF).\n\nExclusion Criteria:\n\n* Pregnancy at the time of screening\n* Previous hysterectomy\n* Known cervical cancer\n* Symptoms of cervical cancer (e.g. metrorrhagia, known pelvic mass)\n* Conditions that can interfere with visualization of the cervix\n* Severe pre-existing medical conditions (e.g. advanced cancer, terminal renal failure)\n* Women who are not able to comply with the study protocol.",true,"FEMALE","25 Years","50 Years",{"count":21,"type":22},1800,"ESTIMATED","INTERVENTIONAL",[25],"NA","This study evaluates the diagnostic accuracy and feasibility of a same-day cervical cancer screening strategy using HPV self-sampling followed by digital telecytology triage among HPV-positive women in Cameroon. Women aged 30-49 years (or 25-49 years if HIV-positive) will undergo primary HPV testing using the GeneXpert system. HPV-positive women will be managed according to an extended HPV genotyping-based algorithm, including immediate treatment, telecytology triage, or follow-up. Histological assessment serves as the reference standard for the detection of cervical intraepithelial neoplasia grade 2 or worse (CIN2+). Secondary objectives include evaluation of AI-assisted telecytology and visual inspection with acetic acid (VIA), as well as the acceptability of screening and treatment strategies among women and healthcare providers. The study aims to generate evidence to support scalable, WHO-recommended test-triage-treat approaches in low-resource settings",[28,29,30],"Human Papillomavirus Infection","Cervical Intraepithelial Neoplasia Grade 2 (CIN2)","Cervical Cancer Screening Methods",[32,33,34,35,36],"HPV self-sampling","Telecytology","Artificial intelligence","Extended HPV genotyping","Low-resource settings","RECRUITING","2026-04-17",{"date":40,"type":41},"2026-04-24","ACTUAL",{"date":43,"type":41},"2025-09-08",{"date":45,"type":22},"2027-09-08",{"name":47,"class":48},"University Hospital, Geneva","OTHER",2,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":59,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":77,"leadSponsor":79,"locationsCount":81},"100590550","ameliorated-pap-tests-and-cervical-cancer-screening-participation-100590550","NCT06968871","Ameliorated Pap Tests and Cervical Cancer Screening Participation","Effects of the Ameliorated Pap Test on Cervical Cancer Screening Participation: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged 25 or above\n\nExclusion Criteria:\n\n* Ongoing menstruation\n* Pregnancy\n* Incapability of understanding the numeric pain scales\n* Any active cancer at study entry (defined as cancer diagnosed or treated within the previous 6 months, recurrent, regionally advanced or metastatic cancer)\n* Previous hysterectomy, pelvic surgery, or radiotherapy\n* Active vaginal or uterus infection\n* Analgesic use within 24 hours",{"count":58,"type":22},248,[25],"The Pap test plays a crucial role in the early detection of cervical cancer. A pilot single-center randomized controlled trial applied the peak-end concept and added a non-painful step at the end of Pap smear screening, aimed to reduce recalled pain. However, there is still no multicenter study investigating the effect of the modified Pap test on cervical cancer screening participation.\n\nThe present project is the first multicenter randomized controlled trial to expand the current scope of the peak-end theory into Pap tests and cervical cancer screening participation by adding a non-painful step at the end of Pap smear screening. Our multidisciplinary team (NTUH Pap Study Group) aims to provide innovative, feasible, and low-cost strategies for cervical cancer screening participation.",[62,30],"Cervical Cancer Screening",[64,65,66,67,68,69,70,71,72],"Cancer screening participation","Cervical cancer","Multicenter","Multidisciplinary","Pain","Pap smear","Peak-end concept","Preventive medicine","Randomized controlled trial","2026-03-01",{"date":75,"type":41},"2026-03-03",{"date":73,"type":22},{"date":78,"type":22},"2032-12-31",{"name":80,"class":48},"National Taiwan University Hospital",5,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":91,"phases":4,"briefSummary":92,"conditions":93,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100469266","project-continuity-promoting-evidence-based-cancer-screening-among-underserved-women-100469266","NCT05390567","Project CONTINUITY: Promoting Evidence-Based Cancer Screening Among Underserved Women","Inclusion Criteria:\n\n1. Using the American Cancer Society (ACS) screening recommendations, adults 25 to 65 will be eligible.\n2. Assigned sex at birth is female\n3. No previous history of cervical cancer\n4. No previous history of a hysterectomy\n5. Not currently pregnant (self-report)\n6. Not currently menstruating\\*\n7. Have not used any vaginal products (e.g., oil-based lubricants, antifungal, and douches) in prior 2 days\\*. Use of vaginal contraceptives, condoms and water-based lubricants are allowed.\n8. Have not given birth in the prior 12 weeks\\*\n9. Self-report they have not undergone cancer screening in the past 4 years or more OR report being past due according to provider recommended screening schedule.\n10. Self-report of using the MOC in the past, no current usual source of care OR usual source of care is a non-UFH provider and\u002For cervical cancer screening is not accessible through that provider\n11. Reside in census tracts where the Mobile Outreach Clinic travels.\n12. Have a mobile phone or access to a mobile phone that can be used to receive messages or a valid email address.\n\nExclusion Criteria:\n\n* For patients who are excluded for criterion 6, 7, and 8, the outreach team (community clinical navigator and CHW) will ask the participant if they can be re-contacted for potential future study eligibility assessment. If the participant agrees, the navigator or CHW will collect contact information to re-contact the participant at a later (pre-determined) date up to 20 weeks later for eligibility screening.","65 Years",{"count":90,"type":22},800,"OBSERVATIONAL","Project CONTINUITY (Connecting You to Care in the Community) was developed to increase adherence to cervical cancer screening regimens from initial screening to needed follow-up care by (1) providing personalized approaches to improve adherence through the combined use of patient choice for the initial screening method (Pap\u002FHPV co-testing vs. HPV self-test collection), community clinical navigators and community health workers (CHWs), customized messages and support for patient portal access for test results and (2) implementing strategies to address social determinants of health (SDoH) that may influence an individual's ability to adhere to the screening regimen, with an initial focus on removing transportation barriers through the use of a mobile outreach clinics (MOC).",[30],"2025-07-08",{"date":96,"type":41},"2025-07-11",{"date":98,"type":41},"2024-06-07",{"date":100,"type":22},"2027-12-01",{"name":102,"class":48},"University of Florida",1]